Key result
Genetic biomarkers show potential to outperform traditional biomarkers for HF diagnosis and prognosis.
Why the study?
Heart failure diagnosis and prognosis by clinical presentation alone are challenging due to nonspecific signs and symptoms, while advancing high-throughput DNA sequencing provides potential for genetic biomarker development.
Do genetic biomarkers improve the diagnosis and prognosis of heart failure compared to traditional biomarkers?
Systematic Review
Do genetic biomarkers improve the diagnosis and prognosis of heart failure compared to traditional biomarkers?
Genetic biomarkers show potential as noninvasive diagnostic and prognostic tools for heart failure, potentially offering higher specificity and sensitivity than traditional biomarkers.
Patients with heart failure (HF) often present with signs and symptoms that are often nonspecific and with a wide differential diagnosis, making diagnosis and prognosis of HF by clinical presentation alone challenging. Our knowledge on genetic diversity is rapidly evolving with high-throughput DNA sequencing technology, which makes a great potential for genetic biomarker development. The present review attempts to provide a comprehensive review on the modification of major genetic components in HF patients and to explore the potential application of these components as clinical biomarkers in the diagnosis and in monitoring the progress of HF. The literature search was conducted using six databases, resulting in the inclusion of eighteen studies in the review. The findings of these studies were summarized narratively. An appraisal of the reporting quality of the included studies was conducted using a twelve-item checklist adapted from the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist. The findings showed that changes in genetic components in patients with HF compared to healthy controls could be noninvasive diagnostic or prognostic tools for HF with higher specificity and sensitivity in comparison with the traditional biomarkers. This review provided evidence for the potential of developing genetic biomarkers of HF.
No takes yet. Share an insight, caveat, or question.
Chair et al. (2021) conducted a systematic review in Heart failure. Genetic biomarkers vs. Traditional biomarkers was evaluated on Diagnostic and prognostic utility of genetic components. Genetic biomarkers in patients with heart failure showed potential as noninvasive diagnostic or prognostic tools with higher specificity and sensitivity compared to traditional biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: